Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
Acromegaly is a rare disease with a multifaceted clinical presentation. In 90–95% of patients with acromegaly, the disease is caused by a growth hormone (GH)-secreting pituitary adenoma with elevated GH levels that ultimately induce excessive hepatic secretion of insulin-like growth factor-1 (IGF-1)...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer US
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094533/ |